Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China barred sales of the company’s gene-sequencing machines. San Diego ...
18d
Zacks Investment Research on MSNILMN Stock Might Rise From Collaboration With Broad Clinical LabsIllumina, Inc. ILMN recently entered into a collaboration with Broad Clinical Labs to rapidly streamline and scale single-cell projects with cutting-edge tools and workflows. Together, the companies ...
Over the last six months, ANGLE has overcome technical issues to successfully use Illumina assays, coupled with their next generation sequencing (NGS) platform, to provide a complete solution for ...
Over the last six months, Angle has overcome technical issues to successfully use Illumina assays, coupled with their next generation sequencing (NGS) platform, to provide a complete solution for the ...
"Illumina has set the standard in whole genome sequencing, and now, with Broad's deep experience and long history of translating complex molecular biology assays into high-throughput, high quality ...
The Chinese government took its economic sanctions against San Diego-based Illumina a step further Tuesday by banning the gene-sequencing company from importing its machines to the country.
The pilot program is based on Illumina's upcoming proteomics assay, Illumina Protein Prep™, powered by SOMAmer® technology, a next-generation sequencing (NGS) based solution that will help ...
Over the last six months, ANGLE has overcome technical issues to successfully use Illumina assays, coupled with their next generation sequencing (NGS) platform, to provide a complete solution for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results